Thus, DIM-3,5 derivatives simultaneously suppress NR4A1- and NR4A2-dependent endometriosis progression effectively and represent a promising non-hormonal therapeutic strategy to replace current hormone-based treatments, that can be associated with adverse effects. This evidence concerns the gene NR4A2 and endometriosis.